P-153 Poster of distinction

9 year follow up of simultaneous kidney and pancreas transplantation in patients with type 1 and type 2 diabetes at a single center

P. Patel, W. Bry, A. Hassoun, R. Peddi, S. Katznelson, L. Bohannon, L. Lu, V. Warvariv, H. Mahanty, K. Ueda, M. Kaszpurenko
California Pacific Medical Center, Transplantation, San Francisco, CA, USA

Objective: Simultaneous kidney and pancreas transplantation (SPK) is commonly offered to patients with end stage renal disease (ESRD) and type 1 diabetes mellitus. Our center has been performing SPK for patients with type 1 and type 2 diabetes since 2002. We compared patient and graft outcomes based on diabetes type in patients who underwent SPK from 2002 through 2010.

Methods: All patients who underwent first SPK consecutively from 2002 through 2010 were identified using standard patient tracking records. Patients were divided into type 1 or type 2 diabetes based on clinical history (diabetes onset, length of insulin dependence, and C-peptide levels). We compared patient, kidney, and pancreas graft survival between the two groups. Pancreas graft failure was defined as return to insulin dependence and kidney graft failure was defined as return to dialysis dependence.

Results: Of 176 patients who underwent SPK, 135 had type 1 diabetes and 41 had type 2 diabetes. A total of 10 deaths occurred, 7 in the type 1 group and 3 in the type 2 group. In patients with type 1 diabetes, 4 died from sepsis, 1 from mucormycosis, and 2 were unknown. In patients with type 2 diabetes, the cause of death was pneumonia, sepsis, and unknown. With a mean follow up of 3.9 years, patient survival was 95% and 92.5% for type 1 and type 2 patients, respectively. Pancreas graft survival was 84% and 78% for type 1 and type 2 patients, respectively. Kidney graft survival was 95% and 92% for type 1 and type 2 patients, respectively.

Conclusions: Our review of 176 patients, 135 with type 1 diabetes and 41 with type 2 diabetes, who underwent first SPK from 2002 through 2010 shows excellent patient and graft survival rates.

P-153 Poster of distinction

9 year follow up of simultaneous kidney and pancreas transplantation in patients with type 1 and type 2 diabetes at a single center

P. Patel, W. Bry, A. Hassoun, R. Peddi, S. Katznelson, L. Bohannon, L. Lu, V. Warvariv, H. Mahanty, K. Ueda, M. Kaszpurenko
California Pacific Medical Center, Transplantation, San Francisco, CA, USA

Objective: Simultaneous kidney and pancreas transplantation (SPK) is commonly offered to patients with end stage renal disease (ESRD) and type 1 diabetes mellitus. Our center has been performing SPK for patients with type 1 and type 2 diabetes since 2002. We compared patient and graft outcomes based on diabetes type in patients who underwent SPK from 2002 through 2010.

Methods: All patients who underwent first SPK consecutively from 2002 through 2010 were identified using standard patient tracking records. Patients were divided into type 1 or type 2 diabetes based on clinical history (diabetes onset, length of insulin dependence, and C-peptide levels). We compared patient, kidney, and pancreas graft survival between the two groups. Pancreas graft failure was defined as return to insulin dependence and kidney graft failure was defined as return to dialysis dependence.

Results: Of 176 patients who underwent SPK, 135 had type 1 diabetes and 41 had type 2 diabetes. A total of 10 deaths occurred, 7 in the type 1 group and 3 in the type 2 group. In patients with type 1 diabetes, 4 died from sepsis, 1 from mucormycosis, and 2 were unknown. In patients with type 2 diabetes, the cause of death was pneumonia, sepsis, and unknown. With a mean follow up of 3.9 years, patient survival was 95% and 92.5% for type 1 and type 2 patients, respectively. Pancreas graft survival was 84% and 78% for type 1 and type 2 patients, respectively. Kidney graft survival was 95% and 92% for type 1 and type 2 patients, respectively.

Conclusions: Our review of 176 patients, 135 with type 1 diabetes and 41 with type 2 diabetes, who underwent first SPK from 2002 through 2010 shows excellent patient and graft survival rates.